254 related articles for article (PubMed ID: 36038416)
21. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
[TBL] [Abstract][Full Text] [Related]
22. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
23. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
[TBL] [Abstract][Full Text] [Related]
24. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Huber RM; Hansen KH; Paz-Ares Rodríguez L; West HL; Reckamp KL; Leighl NB; Tiseo M; Smit EF; Kim DW; Gettinger SN; Hochmair MJ; Kim SW; Langer CJ; Ahn MJ; Kim ES; Kerstein D; Groen HJM; Camidge DR
J Thorac Oncol; 2020 Mar; 15(3):404-415. PubMed ID: 31756496
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.
Yu Y; Zhu F; Zhang W; Lu S
J Clin Med; 2022 May; 11(11):. PubMed ID: 35683354
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
Gupta N; Reckamp KL; Camidge DR; Kleijn HJ; Ouerdani A; Bellanti F; Maringwa J; Hanley MJ; Wang S; Zhang P; Venkatakrishnan K
Clin Transl Sci; 2022 May; 15(5):1143-1154. PubMed ID: 35041775
[TBL] [Abstract][Full Text] [Related]
27. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
28. From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting.
Lee ATM; Ou SI
Lung Cancer (Auckl); 2023; 14():57-62. PubMed ID: 37377783
[TBL] [Abstract][Full Text] [Related]
29. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
31. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
32. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
33. Indirect comparisons of brigatinib and alectinib for front-line
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
[TBL] [Abstract][Full Text] [Related]
34. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.
Hoy SM
Drugs; 2021 Feb; 81(2):267-275. PubMed ID: 33528789
[TBL] [Abstract][Full Text] [Related]
35. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
37. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
38. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
[TBL] [Abstract][Full Text] [Related]
39. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
40. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Yang Y; Min J; Yang N; Yu Q; Cheng Y; Zhao Y; Li M; Chen H; Ren S; Zhou J; Zhuang W; Qin X; Cao L; Yu Y; Zhang J; He J; Feng J; Yu H; Zhang L; Fang W
Signal Transduct Target Ther; 2023 Aug; 8(1):301. PubMed ID: 37574511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]